Review of advances in chemotherapy for thyroid cancer
10.3760/cma.j.cn.115807-20211210-00379
- VernacularTitle:甲状腺癌化学治疗研究综述
- Author:
Fang YU
1
;
Ziyi FAN
;
Yunhan MA
;
Gang WANG
;
Qingqing HE
Author Information
1. 解放军联勤保障部队第九六〇医院甲状腺乳腺外科，济南 250031
- Keywords:
Thyroid cancer;
Cytotoxic drug;
Chemotherapy;
Combination therapy
- From:
Chinese Journal of Endocrine Surgery
2023;17(1):117-119
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of thyroid cancer has continued to increase. Most thyroid cancer patients have good prognosis, but there are still some patients who will develop into the middle or late stage. The status of cytotoxic treatment in thyroid cancer treatment is controversial. Chemotherapy, as a classical malignant tumor treatment, has its unique significance for the special type and the special period of thyroid cancer. Chemotherapy can be an option for systemic treatment if no other treatment is available for patients of differentiated thyroid carcinoma refractory to radiodine in rapid progression and life-threatening period. For patients of anaplastic thyroid cancer in progression period, chemotherapy can be selected if there are no other treatments in clinical trials. And "Chemical therapy plus" treatment model might play an important role in thyroid treatment, because with the development of targeted drugs and immunotherapy, chemotherapy combined with other treatments can reduce the dosage of chemotherapy drugs to reduce the toxic side effect, and can improve other therapeutic effects.
